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Background: The objective of this study was to compare the dose distributions of RapidArc (RA), static gantry
intensity-modulated radiotherapy (IMRT), and three-dimensional conformal radiotherapy (3DCRT) as adjuvant
radiotherapy modalities for the treatment of gastric cancer.
Methods: Fifteen patients with gastric cancer that underwent limited lymphadenectomy of perigastric lymph
nodes were included in this study. Dosimetric values for a total dose of 45 Gy (1.8 Gy/day) were calculated for
the RapidArc, IMRT, and 3DCRT modalities. The following parameters were compared: D99%, D1%, V95%, V107%, and
conformity and homogeneity index values (CI and HI, respectively) for the planned target volume (PTV). Dose
volume histogram (DVH) and dose distribution of the organs at risk (OAR), as the maximal dose to the spinal
cord, V30 and V40 of the small bowel, and V20, V30 of liver and kidney were also assessed respectively.
Results: RA, IMRT, and 3DCRT all achieved desirable PTV coverage. However, RA and IMRT significantly decreased
D1% and V107%, and provided better CI and HI values compared with 3DCRT (P <0.05). Moreover, RA also achieved
a significantly lower maximum dose for the spinal cord, liver V30, and kidney V20 compared to IMRT and 3DCRT;
while the mean dose for these three organ types did not differ for the RA, IMRT, and 3DCRT plans.
Conclusions: Both RA and IMRT achieved favorable PTV coverage compared to 3DCRT. In addition, RA achieved
better dosimetry than IMRT and 3DCRT, and provided better protection for the spinal cord, liver, and kidneys.
Keywords: Double-arc volumetric modulated arc therapy, Intensity-modulated radiotherapy, Three-dimensional
conformal radiotherapy, Gastric cancerBackground
The INT0116 study revealed the survival benefits of
postoperative radiotherapy for gastric cancer patients
[1, 2]. Moreover, both the 3-year and 11-year follow-up
results affirmed the overall survival and disease-free
survival benefits of radiotherapy [1, 2]. Despite these
results, however, gastric cancer radiotherapy remains
controversial. Specifically, concerns remain regarding
radiation-induced toxicity. The toxicity levels reported* Correspondence: wudajianzhu2004@163.com
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unless otherwise stated.for the INT0116 study included grade 3 (40 %), grade 4
(32 %), and gastrointestinal toxicity (33 %), and three
cases involved treatment-related deaths. Consequently,
treatment-related toxicity remains a limiting factor for
the application of gastric cancer radiotherapy [1].
In recent years, three-dimensional conformal radio-
therapy (3DCRT) and intensity modulated radiotherapy
(IMRT) have been widely used for the treatment of can-
cer. These techniques address the drawbacks of conven-
tional anteroposterior-posteroanterior techniques, such
as under-dosage of target regions and excessive radiation
to surrounding normal structures. An advantage of
IMRT technology over 3DCRT for the treatment of
nasopharyngeal carcinoma, prostate cancer, and lungThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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target area, better dose hotspot control, and reduced ra-
diation exposure to organs at risk (OAR), including the
brain stem and spinal cord [3–5]. However, it continues
to be debated whether IMRT or 3DCRT is better for
gastric cancer radiotherapy [6, 7]. In our previous study,
IMRT was found to provide better target uniformity and
conformality than four-field 3DCRT. However, IMRT
did not reduce the dose applied to the OAR (e.g., the
liver and kidneys) [8]. Therefore, the availability of new
technologies is of great interest.
RapidArc (RA) is a type of dynamic IMRT that in-
volves application of a rotation beam according to Otto’s
rotation theory of intensity-modulated radiation therapy.
Briefly, by dynamically changing the gantry rotation
speed, the shape of the multi collimator leaves, and the
dose rate, RA can rapidly and efficiently achieve superior
radiation dose distribution [9]. As such, RA technology
has the potential to shorten treatment time and reduce
the possibility of target movement during treatment,
thereby increasing treatment accuracy. Currently, the lit-
erature available regarding RA mainly focuses on the
treatment of breast, prostate, and lung cancer [10–12]. In
contrast, only a few studies have reported clinical applica-
tions of RA for gastric cancer [13].
To date, neither 3D-CRT nor IMRT have shown a clear
advantage in gastric cancer radiotherapy. This is mostly
attributed to the extensive region of the OAR that is in-
volved. It also remains to be determined whether RA tech-
nology would improve the outcome of gastric cancer
radiotherapy. Therefore, the goal of this study was to com-
pare the dose distribution of RA, static gantry IMRT, and
3DCRT for the radiotherapy treatment of gastric cancer
using dosimetric analysis, and to evaluate which external
radiation technology is best for the postoperative treat-
ment of gastric cancer.
Methods
Patients
Between October 2010 and December 2011, 15 gastric can-
cer patients who underwent D1 surgery at our hospital
were enrolled in this study. According to the 2010 AJCC
staging manual for gastric cancer [14], there were 6 T3
stage patients and 9 T4 stage patients. In addition, the
lymph nodes in 7/9 patients were negative. The primary tu-
mors were located in the cardia (n = 4), the pylorus (n = 6),
or in the gastric body (n = 5). For this retrospective study,
all of the patients completed 3D-CRT treatment before
December 2011. Based on the CT images that were col-
lected, three different treatment plans (3DCRT, IMRT,
and RapidArc) were generated in order to compare the
dose distributions of each. This study was approved by
the ethics committee of the hospital and informed con-
sent was obtained from all of the patients.Patient positioning
Each patient achieved a supine position with their hands
over their chest. This position was then fixed using a
thermoplastic mask. Patients fasted 4 h before the simu-
lation computed tomography (CT) scans, and they were
administered iohexol in 200 ml water orally 10 min be-
fore positioning. Enhanced CT scans were performed
with a slice thickness of 3 mm. CT images were trans-
ferred to the Aria Network (Varian system) and were
reconstructed using the ECLIPSE treatment planning
system (Version 11, Varian Medical System, Palo Alto,
CA, USA).
Target and OAR delineation
According to Report 62 [15] of the International Commis-
sion on Radiation Units and Measurements that refers to
CT and other imaging methods, clinical target volume
(CTV) included the anastomosis, tumor bed, and regional
lymph nodes. The planning target volume (PTV) was de-
fined as a uniform 5 mm expansion of the CTV. The liver,
left kidney, right kidney, spinal cord, small intestine, heart,
and other OAR were delineated step-by-step as previously
described [16].
Treatment planning
Three radiotherapy treatment plans were generated
using the Varian Eclipse treatment planning system
(Version 11, Varian Medical System, Palo Alto, CA,
USA) by an experienced physicist. For each of the plans,
6 MV photon beams from a Trilogy machine (Varian
Medical System) were used and dose calculations were
performed using the Acrous XB algorithm. For 4-field
3DCRT, the center of the PTV was designated the center
of the irradiation field. The box technique in 3DCRT
was found to better protect the OAR compared with half
beam techniques and the use of wedges. Therefore, in
this study, the box technique was selected and the inci-
dent angles used were 0°, 90°, 180°, and 270°. The dose
applied at the center of the central plane was also set as
the reference. For fixed-field sliding window IMRT, the
gantry angle was fixed at 0°, 35°, 90°, 180°, and 315°. For
RA, the coplanar double arc included 358° of rotation
therapy, with 179° as the starting angle and 330° as the
end angle. A maximum dose rate of 600 monitor units
(MU)/min was applied. For all three plans, the pre-
scribed dose for the PTV was 45 Gy/25 F. This dose was
established to ensure that >95 % of the PTV received
45 Gy, and 99 % of the PTV received >42.75 Gy. For the
OAR, less than 30 % of the whole liver volume was
allowed to receive > 30 Gy (V30 ≤30 %). For the contra-
lateral kidney, the volume exposed to more than 20 Gy
was also limited to <30 % (V20 <30 %). The allowed mean
dose (Dmean) for each kidney was <18.0 Gy, and the max-
imum allowed dose for the spinal cord was <45 Gy.
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mized during the generation of the radiotherapy treat-
ment plans. The V40 and V25 for the heart were <30 %
and <50 %, respectively [16, 17].
Evaluation and comparison of the three treatment plans
Dose distributions to the target organs and the OAR for
the fifteen patients were assessed. Dose volume histo-
grams (DVH) were also generated and compared, with
the specific dosimetry parameters evaluated as follows:
To evaluate target coverage, the dose received by 99 %
and 1 % of the volume (e.g., D99% and D1%, respectively)
were defined as metrics for the minimal and maximal
doses [18]. The volumes receiving at least 95 % and
107 % of the prescribed dose (V95% and V107%, respect-
ively), as well as target homogeneity and conformal
index values (HI and CI, respectively), were also com-
pared. HI was calculated as: HI = (D2–D98)/D50. The
greater the HI value, the poorer the uniformity of the
dose distribution [19]. CI was calculated as follows:
VT, ref/VT × VT, ref/Vref, where VT,ref is the volume of
target covered by the reference isodose line, VT is the
target volume (= PTV), and Vref is the volume of tissue
covered by the reference isodose line. The value of CI
varies between 0 and 1, and a value closer to one indi-
cates better conformity of dose to the PTV [20, 21].
The equivalent uniform dose (EUD) for each PTV was
compared.
Dose distribution to vital organs, including kidneys,
liver, small intestine, and spinal cord, were also assessed.
The parameters that were compared included mean dose
(Dmean) and V20 for the kidneys (V20 is the percentage
volume of the kidneys that received at least 20 Gy),
Dmean and V30 for liver, V30 and V40 for small intestine,
and maximum dose (Dmax) and D1% for the spinal cord.
Monitor units (MU) were also compared between three
plans.
Statistical analysis
SPSS (version 17.0, SPSS Inc., Chicago, IL, USA) was
used for data analysis. Non-parametric Wilcoxon tests
or two-tailed t-tests were performed to compare groups.




All three plans fulfilled the dose requirement, and there
were no significant differences in the D99% minimum
dose and the V95% target volume between them. How-
ever, the RA plan did significantly reduce the maximum
target dose and the high dose volume (e.g., D1% and
V107%, respectively) compared to the 3DCRT and IMRT
plans, and the difference between the 3DCRT and IMRTplans was not significant. Both IMRT and RA significantly
lowered the EUD of the PTV compared to 3DCRT
(P <0.05). Regarding target uniformity, both IMRT and
RA also improved the PTV uniformity compared to
3DCRT (P <0.05). In addition, the CI values were 0.91 ±
0.02 for RA, 0.89 ± 0.04 for IMRT, and 0.71 ± 0.01 for
3DCRT. The former was significantly closer to a value of 1
compared with the IMRT and 3DCRT plans (P <0.05)
(Tables 1 and 2; Figs. 1 and 2).
Evaluation of OAR
Previous research has shown that the Dmean and V30 for
the liver are important predictors of radiation-induced
liver damage [8]. In the present study, V30 for the liver
was (12.32 ± 1.61) % for 3DCRT, (12.73 ± 1.33) % for
IMRT, and (6.90 ± 1.41) % for RA. The latter was signifi-
cantly lower than the other two methods (P <0.05). In
addition, the Dmean for the liver was 17.61 ± 0.82 Gy for
3DCRT, 14.22 ± 0.23 Gy for IMRT, and 15.31 ± 1.11 Gy
for RA. Both IMRT and RA reduced the average radi-
ation dose for the liver, yet the difference was not sig-
nificant (Tables 1 and 2; Fig. 2). In a previous study by
Matzinger and Dawson [16, 17], the recommended tol-
erance doses for the kidneys were V20 <30 % and
Dmean <18 Gy. In the present study, the V20 for the left
or right kidney with the RA plan was lower than that
for the IMRT and 3DCRT plans. Specifically, RA treat-
ment decreased the V20 of the left kidney by 25.17 %,
and the right kidney by 33.94 %. In addition, the aver-
age dose for both kidneys was higher for both the
IMRT and RA plans compared to 3DCRT, although the
difference was not significant (P >0.05) (Tables 1 and 2;
Fig. 2).
The V30 and V40, as well as the Dmean, for the small in-
testine were also assessed. Compared with 3DCRT,
IMRT and RA only moderately reduced V30 and V40,
and the differences were not significant. In contrast, RA
slightly increased the Dmean of the small intestine, al-
though this difference was also not significant (P >0.05)
(Tables 1 and 2; Fig. 2).
For the spinal cord, all three plans fulfilled the dose re-
quirements. The maximum radiation doses for D1% were
32.98 ± 0.74 Gy for 3DCRT, 31.01 ± 0.29 Gy for IMRT,
and 27.80 ± 0.75 Gy for RA. Compared with 3DCRT, RA
significantly lowered the spinal cord Dmax value by 15.71 %
(Tables 1 and 2; Fig. 2).
Comparison of MU and delivery parameters
The MU for IMRT and RA were 694.25 ± 3.91 and
399.00 ± 6.81, respectively. Thus, RA significantly re-
duced the radiation dose received by 42.5 % compared
with IMRT. However, RA required a greater number of
MU than 3DCRT. In addition, a physical wedge was not
used for the 3DCRT treatments since this could increase
Table 1 Summary of the DVH parameters examined
Parameters 3DCRT Mean ± SD IMRT Mean ± SD RA Mean ± SD
PTV D1% (Gy) 49.9 ± 0.29 48.2 ± 0.17 48.4 ± 0.24
D99% (Gy) 40.5 ± 0.43 40.3 ± 0.41 40.1 ± 0.37
V95% (%) 96.6 ± 0.61 98.9 ± 0.33 98.5 ± 0.62
V107% (%) 13.6 ± 3.7 1.02 ± 0.01 1.02 ± 0.01
EUD (Gy) 47.3 ± 0.09 46.8 ± 1.45 46.4 ± 0.06
HI 0.1 ± 0.01 0.05 ± 0.01 0.07 ± 0.01
CI 0.71 ± 0.02 0.89 ± 0.04 0.90 ± 0.02
Normal liver Dmean (Gy) 17.6 ± 0.82 14.2 ± 0.73 15.3 ± 1.1
V30 (%) 12.3 ± 1.6 12.7 ± 1.3 6.90 ± 1.4
Left kidney Dmean (Gy) 13.2 ± 1.21 15.3 ± 0.63 14.1 ± 0.61
V20 (%) 29.9 ± 2.5 27.7 ± 1.8 22.4 ± 3.6
Right kidney Dmean (Gy) 11.9 ± 1.4 13.5 ± 0.65 12.2 ± 0.90
V20 (%) 19.2 ± 1.1 16.2 ± 1.1 12.7 ± 1.3
Small bowel Dmean (Gy) 13.1 ± 0.83 12.4 ± 0.39 13.1 ± 0.76
V30 (%) 17.2 ± 0.61 16.5 ± 0.67 15.6 ± 0.83
V40 (%) 11.0 ± 0.38 9.78 ± 0.93 9.15 ± 0.44
Spinal cord D1% (Gy) 33.0 ± 0.74 31.0 ± 0.29 27.8 ± 0.75
MU 250 ± 3.4 694 ± 3.9 399 ± 6.8
Abbreviations: 3DCRT: 3D conformal radiation therapy; IMRT: intensity-modulated radiation therapy; RA: RapidArc; PTV: planned tumor volume; Dn%: dose received
by n% of the volume; Gy: Gray (unit); Vx%: the volume receiving ≥ x% of the prescribed dose; EUD: equivalent uniform dose; HI: homogeneity index; CI: conformity
index; Dmean: the mean dose for the organ; Vn: the volume receiving n dose of radiation (Gy); MU: monitor units; EUD: equivalent uniform dose
Table 2 Differences among the three methods with regard to the DVH parameters
Parameters P-values
Overall 3DCRT vs. IMRT 3DCRT vs. RA IMRT vs. RA
PTV D1% (Gy) 0.003 3DCRT > IMRT** 3DCRT > RA** −
D99% (Gy) 0.803 − − −
V95% (%) 0.533 − − −
V107% (%) 0.005 3DCRT > IMRT* 3DCRT > RA* −
EUD (Gy) 0.012 3DCRT > IMRT* 3DCRT > RA* _
HI 0.03 3DCRT > IMRT* 3DCRT > RA* −
CI 0.001 3DCRT < IMRT* 3DCRT < RA* −
Normal liver Dmean (Gy) 0.058 3DCRT > IMRT** − −
V30 (%) 0.006 − 3DCRT > RA** IMRT > RA**
Left kidney Dmean (Gy) 0.335 − − −
V20 (%) 0.137 − 3DCRT > RA* −
Right kidney Dmean (Gy) 0.912 − − −
V20 (%) 0.005 − 3DCRT > RA** −
Small bowel Dmean (Gy) 0.657 − − −
V30 (%) 0.075 − − −
V40 (%) 0.453 − − −
Spinal cord D1% (Gy) 0.011 − 3DCRT > RA* IMRT > RA*
MU 0.001 IMRT > 3DCRT** IMRT > RA**
Abbreviations: 3DCRT: 3D conformal radiation therapy; IMRT: intensity-modulated radiation therapy; RA: RapidArc; PTV: planned tumor volume; Dn%: dose received
by n% of the volume; Gy: Gray (unit); Vx%: the volume receiving ≥ x% of the prescribed dose; EUD: equivalent uniform dose; HI: homogeneity index; CI: conformity
index; Dmean: the mean dose for the organ; Vn: the volume receiving n dose of radiation (Gy); MU: monitor units
*P <0.05; **P <0.01
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Fig. 1 Comparison of the PTV isodose distributions achieved with 3DCRT, IMRT, and RapidArc adjuvant radiotherapy modalities
Fig. 2 Mean dose volume histograms for PTV, CTV, OAR, and healthy tissue for global analysis according to treatment plan. 3DCRT: 3D conformal
radiation therapy (blue); IMRT: intensity-modulated radiation therapy (red); RapidArc: double-arc RapidArc (green)
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tial for leakage radiation (Tables 1 and 2). The dose rate
for each technique was 400 MU/min for 3DCRT, 600
MU/min for IMRT, and nearly 600 MU/min for ARC.
Thus, the relative treatment times for each technique
were: 3.2 ± 0.3 min for RA, 6.6 ± 1.2 min for IM, and
4.2 ± 0.5 min for CRT.
Discussion
Currently, postoperative chemoradiation is one of the
main treatments for cases of gastric cancer with poor
prognosis. However, due to the proximity of this region
to many vital organs, it remains a challenge to effectively
cover the target area and protect neighboring vital or-
gans. For adjuvant radiotherapy modalities, it has been
difficult to achieve an ideal dose distribution with trad-
itional 3DCRT, while IMRT is able to simultaneously
optimize target dose and decrease exposure of OAR.
IMRT has also been shown to effectively improve local
tumor control, to reduce the extent of radiation damage
to normal tissues, and to improve patient quality of life
[22]. However, in our previous study of 3DCRT and
IMRT for the treatment of gastric cancer, radiation
dosimetry data indicated that IMRT did not show a
significant advantage over 3DCRT, with 3DCRT being
superior to IMRT for V20 of the left and right kidneys
[8]. Therefore, new radiotherapy techniques for the
treatment of gastric cancer are still needed.
RA technology has the potential to shorten treatment
time and reduce the possibility of target movement dur-
ing treatment, which would serve to increase treatment
accuracy [18]. RA has previously been applied to the
treatment of many types of tumors [23, 24]. For ex-
ample, in work by Verbakel et al. [25], twelve patients
with advanced head and neck cancer received IMRT ver-
sus RA radiation therapy. Treatment with RA was found
to improve target dose uniformity and to reduce expos-
ure of neighboring OAR. Furthermore, double arc RA
provided additional dosimetric advantages compared to
single arc RA and IMRT. These advantages were con-
firmed with the treatment of lung cancer and prostate
cancer with double arc RA [11, 12]. However, for gastric
cancer radiation therapy, the shape of the radiation tar-
get is irregular and the surrounding organs, including
the liver and kidneys, have a low tolerance for radiation.
Thus, it remains to be determined whether a rotary
volumetric IMRT technique will be advantageous for
gastric cancer radiotherapy.
The cohort studied included 15 postoperative gastric
cancer patients. Based on the location of their lesions
and CT imaging, 3DCRT (4-field), IMRT (5-field), or
RA treatment plans were applied. The prescription dose
included 45 Gy/25 F applied to the PTV, with >95 % of
the PTV receiving 45 Gy and 99 % of the PTV receiving42.75 Gy. All three plans met the dose requirements and
there were no significant differences between them. Fur-
thermore, IMRT and RA reduced the target maximum
dose and the high dose range (D1%, V107%) compared to
3DCRT. IMRT and RA were also superior to 3DCRT for
target volume uniformity. The CI value for RA was sig-
nificantly closer to one than the CI values for IMRT and
3DCRT, suggesting an improved conformality was
achieved. For targets with larger and more complex
shapes, RA was found to provide better dose distribu-
tion, better PTV target conformality, and better target
dose distribution, and these results are consistent with
previous studies [13]. Thus, RA has the potential to re-
duce treatment-related side effects.
In the early studies of organ tolerance to ionizing radi-
ation, radiosensitivity of the liver may have been under-
estimated. Tolerance doses were limited according to
the risk of RT-induced liver disease, and the mean dose
and V30 for the liver were considered important dosi-
metric parameters associated with increased toxicity risk
[26]. Meanwhile, more recent studies have shown that
normal liver cells are sensitive to radiation, especially
when the liver is infected with hepatitis B virus [26]. Ac-
cordingly, Dawson et al. [27] have suggested that the tol-
erance dose for the liver should be less than 30 % for
V30, and the Dmean should be less than 30 Gy. For cases
involving hepatitis B infection, the Dmean should be less
than 23 Gy. Furthermore, according to the Quantitative
Analyses of Normal Tissue Effects in the Clinic (QUAN-
TEC) effort, the mean liver dose should be less than
28 Gy in 2-Gy fractions for primary liver cancer, and
should be less than 32 Gy in 2-Gy fractions for liver
metastases [26]. In the present study, liver V30 was
(12.32 ± 1.61) % for 3DCRT, (12.73 ± 1.33) % for IMRT,
and (6.90 ± 1.41) % for RA, with the latter being signifi-
cantly lower than the two former values (P <0.05). Liver
Dmean was 17.61 ± 0.82 Gy for 3DCRT, 14.22 ± 0.23 Gy
for IMRT, and 15.31 ± 1.11 Gy for RA, and these did
not significantly differ. Compared with 3DCRT and
IMRT, RA significantly reduced liver V30, yet did not
affect the average liver dose. Furthermore, despite the
significant reduction in liver V30, an analysis of volume
from the DVH showed that V10 increased. These results
are consistent with those reported for a liver cancer radi-
ation treatment study performed by Kuo et al. [28].
The kidney is another important organ that is threat-
ened by gastric cancer radiotherapy. Kidney tissue is ra-
diosensitive, and the recommended radiation tolerance
doses are 23 Gy for the whole kidney, 30 Gy for 2/3 of
the kidney, and 50 Gy for 1/3 of the kidney. A study by
Jansen et al. further suggested that the average renal
dose was less important than V20. Therefore, it is recom-
mended that <70 % of the kidney volume should receive
20 Gy (V20 <70 %), while the V20 for the contralateral
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posed to more than 20 Gy should not exceed 50 % of
the whole kidney, otherwise, radiation-induced damage
to the kidney may occur, such as a decrease in the glom-
erular filtration rate and/or renal failure. Thus, an on-
going goal is to reduce the radiation dose to kidneys
during postoperative radiotherapy for gastric cancer.
Minn et al. [30] studied the dosimetry, efficacy, and tox-
icity of radiotherapy planning with 3DCRT and IMRT
for 57 cases of gastric cancer, and IMRT was found to
reduce kidney V20. In our previous study, no obvious
difference in the V20 of kidney between IMRT and 3D-
CRT was observed, although IMRT exhibited favorable
tumor coverage and superiority in protecting the spinal
cord and liver. However, this superiority was not ob-
served in the kidney compared with 3D-CRT. Thus,
IMRT does not appear to represent a superior treatment
for gastric cancer [8]. Similarly, in our subsequent single
arc RA study, kidney radiation dose was not significantly
reduced, yet double arc RA significantly decreased kid-
ney V20 compared to IMRT and 3DCRT for both kid-
neys. Meanwhile, there was no obvious difference in the
Dmean for both kidneys among the 3D-CRT, IMRT, and
RA treatments. Taken together, these results suggest that
RA can provide a protective effect for kidneys compared
to IMRT.
Gastrointestinal toxicity is the main limiting factor for
the application of radiation therapy to gastric cancer.
Correspondingly, the key to reducing toxicity due to
radiotherapy is to control the exposure of the gastro-
intestinal tract to radiation. In many studies, IMRT and
RA have been shown to reduce the radiation dose to the
gastrointestinal tract during abdominal radiation ther-
apy. For example, Minn et al. [30] demonstrated that
IMRT reduced intestinal V45 compared to 3DCRT. In
another study of 14 cases of abdominal metastases
treated with radiation therapy, Mario et al. [30] reported
that RA and IMRT reduced the average dose and max-
imum dose to the stomach and small intestine compared
to 3DCRT. However, the difference was not significant.
In the present study, the average dose (Dmean) for the
small intestine, as well as V30 and V40, were examined.
Dmean for the small intestine did not significantly differ
among the three planning methods, yet a DVH chart
analysis showed that IMRT and RA increased V10 and
reduced V30 and V40 compared to 3DCRT. Thus, the
volume of the low dose region increased concomitant
with a decrease in the volume of the high dose region.
These results are consistent with the observation that
the average dose did not show a significant difference.
The spinal cord is a long, thin, tubular bundle of ner-
vous tissue and it is susceptible to injury from local high
doses of radiation. Kirkpatrick et al. [31] reported that
the incidence rate for radiation myelitis is 0.2, 6, and50 % the total dose for 50 Gy, 60 Gy, and_69 Gy, re-
spectively, when administered at the conventional
fraction of 2-Gy per day. In addition, according to the
Radiation Oncology Group of the European Organisa-
tion for Research and Treatment of Cancer, the max-
imal radiation dose that should be applied to the
spinal cord is 45 Gy, and it should not exceed 40 Gy if
oxaliplatin chemotherapy is administered as well [16].
Therefore, the maximum dose for the spinal cord is
generally set at no more than 45 Gy. In the present
study, the doses applied to the spinal cord with each
of the three techniques were all within the tolerated
dose. Moreover, compared to 3DCRT, the Dmax for the
spinal cord with RA was significantly reduced by up to
15.71 %.
RA is an adjuvant radiotherapy modality that has re-
cently been developed and has been used to deliver high
doses of radiation to a variety of tumors. However, its
role in the treatment of gastric cancer remains contro-
versial due to the irregular target volumes involved and
the low radiation tolerance of surrounding critical or-
gans. In our previous study, RA provided superior dose
homogeneity compared with 3DCRT and IMRT, but not
better protection of the OAR. Moreover, while the single
arc technique was unsuccessful, the double arc tech-
nique was able to achieve the same dose distribution as
IMRT, while significantly sparing the OAR and proximal
healthy tissue. This improved protection of liver and kid-
ney tissues compared with IMRT suggests a higher dose
could be applied to a target volume using double arc
RA. However, it is important to consider the limitations
of our study as well. First, a respiratory gating technique
was not used, and its influence on the dose distribution
was not investigated. In addition, the present study had
a small sample size and did not evaluate clinical efficacy
and toxicity. Therefore, further studies are needed to
confirm the technical feasibility of applying double arc
RA to the treatment of gastric cancer, and these should
include a larger sample size and evaluations of clinical
efficacy and toxicity.
Conclusions
In summary, double arc RA reduced the maximum dose
applied to the target area, it improved the conformality
and uniformity of radiation, and it provided sufficient
PTV coverage. Moreover, compared to 3DCRT and
IMRT, double arc RA significantly reduced liver V30,
kidney V20, and the spinal cord maximum dose. Further-
more, RA was found to provide the best protection from
high doses of radiation. Therefore, in this comparative
study, a theoretical foundation for the clinical applica-
tion of radiation for gastric cancer is demonstrated. Des-
pite the small sample size, the results are very promising
and further studies are needed to confirm these results.
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